RESPIR 4-95

a potent and long-acting bronchodilator; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Berglund, Magnus: 1 article (01/2008)
2.	Dalence-Guzmán, María F: 1 article (01/2008)
3.	Jönsson, Per: 1 article (01/2008)
4.	Mesic, Admira: 1 article (01/2008)
5.	Persson, Carl G A: 1 article (01/2008)
6.	Skogvall, Staffan: 1 article (01/2008)
7.	Sterner, Olov: 1 article (01/2008)
8.	Svensson, Katrin: 1 article (01/2008)

1.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2008 - "Efficacy, potency, duration of action, and inexhaustibility of its relaxation of human small airways make RESPIR 4-95 an interesting lead compound for further developments aiming at drug treatment of small airway obstruction in asthma and COPD. "
2.	Asthma (Bronchial Asthma) 01/01/2008 - "Efficacy, potency, duration of action, and inexhaustibility of its relaxation of human small airways make RESPIR 4-95 an interesting lead compound for further developments aiming at drug treatment of small airway obstruction in asthma and COPD. "
3.	Airway Obstruction (Choking) 01/01/2008 - "Efficacy, potency, duration of action, and inexhaustibility of its relaxation of human small airways make RESPIR 4-95 an interesting lead compound for further developments aiming at drug treatment of small airway obstruction in asthma and COPD. "